189 related articles for article (PubMed ID: 29982521)
21. Broken drug markets in infectious diseases: Opportunities outside the private sector?
Alpern JD; Dunlop SJ; Stauffer WM
PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007190. PubMed ID: 30973876
[TBL] [Abstract][Full Text] [Related]
22. The private sector role in HIV/AIDS in the context of an expanded global response: expenditure trends in five sub-Saharan African countries.
Sulzbach S; De S; Wang W
Health Policy Plan; 2011 Jul; 26 Suppl 1():i72-84. PubMed ID: 21729920
[TBL] [Abstract][Full Text] [Related]
23. Partnerships between philanthropy, government and industry are needed to advance drug discovery for neurodegenerative diseases.
Refolo LM; Fillit HM
Curr Alzheimer Res; 2006 Jul; 3(3):175-6. PubMed ID: 16842090
[No Abstract] [Full Text] [Related]
24. Brazilian healthcare in the context of austerity: private sector dominant, government sector failing.
Costa NDR
Cien Saude Colet; 2017 Apr; 22(4):1065-1074. PubMed ID: 28444034
[TBL] [Abstract][Full Text] [Related]
25. Public-private partnerships for health: their main targets, their diversity, and their future directions.
Widdus R
Bull World Health Organ; 2001; 79(8):713-20. PubMed ID: 11545327
[TBL] [Abstract][Full Text] [Related]
26. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
Coghlan R; Stephens P; Mwale B; Siyanga M
Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
[TBL] [Abstract][Full Text] [Related]
27. The Government and Pharmaceutical Innovation: Looking Back and Looking Ahead.
Sampat BN
J Law Med Ethics; 2021; 49(1):10-18. PubMed ID: 33966646
[TBL] [Abstract][Full Text] [Related]
28. The potential of health sector non-governmental organizations: policy options.
Gilson L; Sen PD; Mohammed S; Mujinja P
Health Policy Plan; 1994 Mar; 9(1):14-24. PubMed ID: 10133097
[TBL] [Abstract][Full Text] [Related]
29. Re-engineering drug discovery and development.
FitzGerald GA
LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
[TBL] [Abstract][Full Text] [Related]
30. Academia-pharma partnerships for novel drug discovery: essential or nice to have?
Palmer M; Chaguturu R
Expert Opin Drug Discov; 2017 Jun; 12(6):537-540. PubMed ID: 28394189
[No Abstract] [Full Text] [Related]
31. Biotech's wellspring--a survey of the health of the private sector in 2014.
Huggett B
Nat Biotechnol; 2015 May; 33(5):470-7. PubMed ID: 25965753
[No Abstract] [Full Text] [Related]
32. INTRODUCTION: Public Sector and Non-Profit Contributions to Drug Development - Historical Scope, Opportunities, and Challenges.
Sarpatwari A; Kesselheim AS
J Law Med Ethics; 2021; 49(1):6-9. PubMed ID: 33966663
[No Abstract] [Full Text] [Related]
33. Addressing Antimicrobial Resistance and Stewardship: The Priority Antimicrobial Value and Entry (PAVE) Award.
Daniel GW; Schneider M; McClellan MB
JAMA; 2017 Sep; 318(12):1103-1104. PubMed ID: 28772301
[No Abstract] [Full Text] [Related]
34. The promise of South African biotech.
Akermann B; Kermani F
Drug Discov Today; 2006 Nov; 11(21-22):962-5. PubMed ID: 17055404
[No Abstract] [Full Text] [Related]
35. The role of the private sector in biotechnology: research and development.
Feisee L
Health Matrix Clevel; 2002; 12(2):357-65. PubMed ID: 12430359
[No Abstract] [Full Text] [Related]
36. Public health finance: a conceptual framework.
Moulton AD; Halverson PK; Honoré PA; Berkowitz B
J Public Health Manag Pract; 2004; 10(5):377-82. PubMed ID: 15552760
[TBL] [Abstract][Full Text] [Related]
37. Overcoming the current deadlock in antibiotic research.
Schäberle TF; Hack IM
Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
[TBL] [Abstract][Full Text] [Related]
38. The financing of dental care--the private/public mix.
Price M
J Dent Assoc S Afr; 1994 Jun; 49(6):277-82. PubMed ID: 9508947
[No Abstract] [Full Text] [Related]
39. A new era of hope for the world's most neglected diseases.
The
PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
[TBL] [Abstract][Full Text] [Related]
40. Sharing the burden of TB/HIV? Costs and financing of public-private partnerships for tuberculosis treatment in South Africa.
Sinanovic E; Kumaranayake L
Trop Med Int Health; 2006 Sep; 11(9):1466-74. PubMed ID: 16930269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
